Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Update

by · The Markets Daily

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN – Get Free Report) saw a large decline in short interest during the month of December. As of December 15th, there was short interest totaling 20,342 shares, a decline of 23.0% from the November 30th total of 26,423 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 4,116 shares, the days-to-cover ratio is presently 4.9 days. Based on an average daily trading volume, of 4,116 shares, the days-to-cover ratio is presently 4.9 days. Currently, 0.1% of the shares of the stock are short sold.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a research report on Monday, December 22nd. JPMorgan Chase & Co. cut their target price on shares of Molecular Partners from $4.00 to $3.75 and set a “neutral” rating on the stock in a report on Monday, December 8th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $7.88.

Check Out Our Latest Stock Report on Molecular Partners

Molecular Partners Price Performance

MOLN stock traded up $0.15 during trading on Wednesday, reaching $4.45. The company had a trading volume of 1,260 shares, compared to its average volume of 4,304. Molecular Partners has a 52 week low of $3.36 and a 52 week high of $5.91. The business has a 50 day moving average of $4.17 and a 200 day moving average of $3.87. The company has a market cap of $179.49 million, a P/E ratio of -2.32 and a beta of 1.08.

Molecular Partners (NASDAQ:MOLN – Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.05. Research analysts expect that Molecular Partners will post -1.93 earnings per share for the current year.

Molecular Partners Company Profile

(Get Free Report)

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.

Recommended Stories